Calcium acetate hydrate, 99.99% trace metals basis

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Calcium acetate hydrate, 99.99% trace metals basis
• 英文别名: calcium;diacetate;hydrate
• 化学式: C4H8CaO5
• 分子量: 176.18
• InChiKey: XQKKWWCELHKGKB-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -3.69
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  81.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Calcium acetate hydrate, 99.99% trace metals basis 以 乙二醇 为溶剂， 反应 3.75h， 生成 Acetic acid, calcium salt, hydrate
  参考文献：
  名称：

  Process for preparing polyesters

  摘要：

  一种制备聚酯的方法，包括在酯交换反应催化剂的存在下，将至少90摩尔％为对苯二甲酸的二低烷基酯与至少90摩尔％为乙二醇的2至10个碳原子的聚亚甲基醇反应，形成酯交换反应产物，然后在聚合催化剂的存在下进行聚缩反应，其中乙二醇中的(A) 20至150毫摩尔％（基于所述二低烷基酯的二官能羧酸）的乙酸钙和(B) 2至25毫摩尔％（基于所述二低烷基酯）的乙酸钴形成酯交换反应催化剂。

  公开号：

  US04058507A1

文献信息

• Inorganic shaped bodies and methods for their production and use
  申请人：——

  公开号：US20030175321A1

  公开（公告）日：2003-09-18

  Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A shaped, inorganic body is formed in situ. Optional, but preferred additional thermal treatment of the shaped, inorganic body removes the organic substrate, leaving an inorganic body that faithfully mimics the porosity, shape, and other physical characteristics of the organic substrate. Inorganic substrates may also be used to good effect. Large varieties of shaped bodies can be prepared in accordance with other embodiments of the invention and such shapes find wide use in surgery, laboratory and industrial processes and otherwise. The invention also provides chemically and morphologically uniform powders, including those having uniformly small sizes.

  本发明提供了一种由反应性混合物制备的形状优选为多孔的无机体。根据一种优选实施例，该溶液被吸收到多孔的牺牲性基质中，例如纤维素海绵中。该溶液饱和的基质被加热，氧化还原反应发生，从而形成无机固体。在原位形成一个形状的无机体。可选的，但是优选的附加热处理形状的无机体去除有机基质，留下一个无机体，其忠实地模拟有机基质的多孔性、形状和其他物理特性。无机基质也可以被有效地使用。根据本发明的其他实施例可以制备大量形状的体，并且这些形状在外科手术、实验室和工业过程以及其他领域中得到广泛应用。本发明还提供了化学和形态均匀的粉末，包括具有均匀小尺寸的粉末。
• Novel compounds
  申请人：Bjork Anders

  公开号：US20060004038A1

  公开（公告）日：2006-01-05

  A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R′ is hydrogen, C 1 -C 4 alkyl, C 1 -C 3 alkoxy; halogen, trifluoromethyl or OCH x F y , R″ is hydrogen, fluoro or chloro, that R″ being fluoro or chloro only when R′ is fluoro or chloro; R 3 is hydrogen or C 1 -C 5 alkyl R 4 is hydrogen, CH 2 OCOC(CH 3 ) 3 , pharmaceutically acceptable inorganic or organic cations, or COR 4 ′ wherein R 4 ′ is C 1 -C 5 alkyl, phenyl, benzyl or phenethyl; R 7 is methyl or ethyl; one of A and B is sulphur and the other is C—R 2 ; when A is S, R 2 is selected from hydrogen and methyl, with the proviso that R 2 is methyl only when R 3 is not hydrogen; and when B is S, R 2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.

  化合物的化学式为(I)，其中R为甲基、乙基、正丙基、异丙基、正丁基或烯丙基；R′为氢、C1-C4烷基、C1-C3烷氧基、卤素、三氟甲基或OCHxFy；R″为氢、氟或氯，当R′为氟或氯时，R″仅为氟或氯；R3为氢或C1-C5烷基；R4为氢、CH2OCOC(CH3)3、药学上可接受的无机或有机阳离子，或COR4′，其中R4′为C1-C5烷基、苯基、苄基或苯乙基；R7为甲基或乙基；A和B中的一个为硫，另一个为C-R2；当A为S时，R2从氢和甲基中选择，但R3不为氢时，R2仅为甲基；当B为S时，R2为氢；以及其任何互变异构体。一种包含化合物(I)的药物组合物，一种治疗恶性肿瘤或由自身免疫或病理性炎症引起的疾病的方法。
• Method for manufacturing dipeptides
  申请人：Sagami Chemical Research Center

  公开号：US04284721A1

  公开（公告）日：1981-08-18

  An improvement in a method for manufacturing dipeptides from an N-substituted aspartic acid and a phenylalanine lower alkyl ester. The two starting materials are allowed to react with each other in the presence of an immobilized metallo-proteinase in an organic solvent immiscible with water. The enzyme can be recovered for reuse thereof. The loss of materials due to the hydrolysis of the phenylalanine lower alkyl ester is reduced, so that use of the phenylalanine lower alkyl ester in a nearly stoichiometric quantity suffices for the reaction to ensure an improved yield and reduction in cost of industrial production.

  一种制备二肽的方法得到改进，该方法使用N-取代天冬氨酸和苯丙氨酸低烷基酯作为起始物质，在有机溶剂中不与水混溶的条件下，让这两种起始物质在固定化金属蛋白酶的存在下相互反应。该酶可以回收并重复使用。由于苯丙氨酸低烷基酯的水解导致的物料损失被减少，因此只需使用接近化学计量量的苯丙氨酸低烷基酯即可确保反应的改进产量和降低工业生产成本。
• Biodegradable terephthalate polyester-poly (phosphate) polymers, compostions, articles, and methods for making and using the same
  申请人：——

  公开号：US20020091230A1

  公开（公告）日：2002-07-11

  Biodegradable terephthalate polymers are described comprising the recurring monomeric units shown in formula I: 1 wherein R is a divalent organic moiety; R′ is an aliphatic, aromatic or heterocyclic residue; x is ≧1; and n is 0-5,000, wherein the biodegradable polymer is biocompatible before and upon biodegradation. Processes for preparing the polymers, compositions containing the polymers and biologically active substances, articles useful for implantation or injection into the body fabricated from the compositions, and methods for controllably releasing biologically active substances using the polymers, are also described.

  本文描述了可生物降解的对苯二甲酸酯聚合物，其中包含公式I:1所示的重复单体单位，其中R是二价有机基；R'是脂肪族、芳香族或杂环残基；x为≥1；n为0-5,000，在生物降解之前和之后，生物降解聚合物是生物相容的。还描述了制备聚合物的方法，含有聚合物和生物活性物质的组合物，用于植入或注射到体内的有用物品，以及使用聚合物可控释放生物活性物质的方法。
• New compositions containing quinoline compounds
  申请人：Jansson Karl

  公开号：US20050192315A1

  公开（公告）日：2005-09-01

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体药物组合物，基本上由公式（II）的盐的有效量和维持pH值在8以上的碱性反应成分或具有二价金属阳离子的盐以及至少一种药用辅料组成；所述公式（II）的盐在室温下储存至少3年期间基本上稳定。稳定公式（II）的盐的方法。公式（II）的结晶盐和制备该盐的方法。